Sunesis Pharmaceuticals


$30.5m market cap

$0.27 last close

Sunesis Pharmaceuticals focuses on oncology. Its lead asset is SNS-510, a PDK1 inhibitor in preclinical studies for a range of solid and hematologic tumors. It recently discontinued the vecabrutinib development program. It has also developed pan-Raf inhibitor TAK-580, currently licensed to DOT Therapeutics.

Investment summary

Sunesis is a pharmaceutical company developing small molecule oncology drugs. Its lead program is SNS-510, a novel PDK1 inhibitor. The company plans to file an IND for the drug and begin clinical trials in 2020. It recently discontinued its vecabrutinib program after seeing limited activity in Phase I.

Y/E Dec
Revenue (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2018A 0.2 (25.7) (26.6) (74.80) N/A N/A
2019A 2.1 (23.3) (23.3) (26.78) N/A N/A
2020E 0.1 (20.0) (19.9) (13.60) N/A N/A
2021E 0.0 (18.4) (19.9) (10.52) N/A N/A
Industry outlook

Sunesis is an oncology company with an early-stage asset with a validated target for the treatment of B-cell malignancies.

Last updated on 01/09/2020
Register to receive research on Sunesis Pharmaceuticals as it is published
Share price graph
Balance sheet
Forecast net cash (US$m) 23.9
Forecast gearing ratio (%) N/A
Price performance
Actual (43.6) (54.4) (79.6)
Relative* (48.1) (60.8) (83.4)
52-week high/low US$11.1/US$1.7
*% relative to local index
Key management
Dayton Misfeldt Interim CEO

Content on Sunesis Pharmaceuticals